The Russian Covid vaccine is ok. The study published in Lancet
The Russian anti Covid attack produces antibodies. What is written in the study of the National Institute of Epidemiological Research Gamaleya of Moscow published in the specialized journal Lancet
The Russian Sputnik vaccine works. To say it is a study published in the Lancet : according to what was reported by the group of Denis Logunov, of the National Institute of Epidemiological Research Gamaleya in Moscow, the vaccine would have produced an immune response in all 76 volunteers, healthy adults between 18 and 60 years. , involved in phases 1 and 2 of the experiment.
Let's go step by step.
I STUDY
The vaccine study, produced by Binnopharm, was led by Denis Y Logunov and colleagues from the NF Gamaleya Research Institute of Epidemiology and Microbiology.
THE EXPERIMENTATION
For the trial, the researchers enrolled 76 healthy adult volunteers (aged 18 to 60) in two different studies (38 people in each study) between 18 June and 3 August; 53 (70%) participants were men and 23 (30%) were women.
The main measures of assessment were safety and immunogenicity (antigen-specific humoral immunity). In phase 1 of each study, two groups of nine volunteers received one dose of the recombinant adenovirus vector type 26 (rAd26) or the recombinant adenovirus vector type 5 (rAd5), both carrying the gene for severe acute respiratory syndrome. coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S), in lyophilized or frozen form.
In phase 2, another group of 20 healthy adult volunteers in each study received sequential doses of rAd26-S followed by rAd5-S of one of the two formulations.
ADVERSE REACTIONS
No serious adverse events. Contraindications were injection site pain (44 [58%]), hyperthermia (38 [50%]), headache (32 [42%]), asthenia (21 [28%]) and muscle and joint pain (18 [24%]), as reported in the Lancet.
THE DEVELOPMENT OF ANTIBODIES
From an immunological point of view, however, in phase 2, 85% of participants had detectable antibodies 14 days after the priming dose, rising to 100% by day 21.
THE LIMITS OF THE STUDY
There is no shortage of limits, reports Lancet . The frozen vaccine was given to young military men, and soldiers are likely to be fitter and healthier than the general population, with no particular symptoms.
In the elderly, however, senescence could make vaccines less immunogenic. However, no elders were included in the study.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/innovazione/il-vaccino-russo-anti-covid-e-ok-lo-studio-pubblicato-su-lancet/ on Fri, 04 Sep 2020 14:53:14 +0000.